GlassScriptPhysician profile
Omar M Dukar
NPI 1609875723
$43,073.59
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $11K · 2021: $9,754 · 2022: $538 · 2023: $605 · 2024: $694 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $24,297.57 | 2019-2021 | |
| Allergan, INC. | $8,814.92 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,213.95 | 2019-2021 | |
| Abbvie INC. | $626.89 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $602.46 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $490.87 | 2019-2025 | Rocklatan, Hydrus Microstent, Centurion |
| Regeneron Healthcare Solutions, INC. | $200.50 | 2019-2022 | |
| Biotissue Holdings INC. | $141.28 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $117.50 | 2019-2023 | Xelpros, Cequa |
| Kala Pharmaceuticals, INC. | $92.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $90.79 | 2020-2023 | |
| Regeneron Pharmaceuticals, INC. | $75.00 | 2023 | Eylea |
| Ani Pharmaceuticals, INC. | $67.55 | 2024 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $64.38 | 2022-2023 | Tyrvaya |
| Amgen INC. | $40.48 | 2024-2025 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $29.81 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $27.12 | 2024 | Xdemvy |
| Dompe US, INC. | $25.69 | 2024 | Oxervate |
| Thea Pharma INC. | $22.22 | 2023 | |
| Shire North American Group INC | $17.85 | 2019 | |
| Horizon Therapeutics Plc | $14.62 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Dukar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.